Novartis AG — Director's Dealing 2018

Jul 27, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AILERON THERAPEUTICS INC (ALRN)
CIK: 0001420565
Period of Report: 2018-07-25

Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-25	Common Stock	S	12460	$3.84	Disposed	2487622	Direct
2018-07-26	Common Stock	S	7937	$3.63	Disposed	2479685	Direct

Footnotes

F1: Reflects sales of common stock executed in multiple transactions at prices ranging from $3.75 to $3.92. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.

F2: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.

F3: Reflects sales of common stock executed in multiple transactions at prices ranging from $3.52 to $3.81. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.